Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.58 |
| ▸ | DRD2 | P14416 | 13/20 | 0.58 |
| ▸ | DRD4 | P21917 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617541 | 0.93 | DRD3 (0.68) | DRD3DRD2DRD4DRD1HTR2A | |
| SCHEMBL4445019 | 0.87 | DRD3 (0.60) | DRD3DRD2DRD4SLC6A2SLC6A4 | |
| SCHEMBL3618645 | 0.87 | DRD2 (0.68) | DRD3DRD2DRD4SLC6A2SLC6A4 | |
| SCHEMBL3614911 | 0.80 | DRD3 (0.86) | DRD3DRD2DRD4MAOAMAOB | |
| SCHEMBL3611072 | 0.77 | DRD2 (0.58) | DRD3DRD2DRD4MAOAMAOB | |
| SCHEMBL1780938 | 0.76 | DRD2 (0.57) | DRD3DRD2DRD4MAOAMAOB | |
| SCHEMBL1114549 | 0.75 | DRD2 (0.52) | DRD3DRD2DRD4MAOAMAOB | |
| SCHEMBL3612201 | 0.74 | DRD2 (0.86) | DRD3DRD2DRD4DRD1HTR2A | |
| SCHEMBL3613041 | 0.74 | DRD2 (0.61) | DRD3DRD2DRD4MAOAMAOB | |
| SCHEMBL12403727 | 0.73 | HRH3 (0.62) | DRD3DRD2DRD4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | claimed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | claimed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | DONSBACH, MARTIN (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137185-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | Gmeiner, Dr. Peter (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113559-A2 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | SCHWARZ PHARMA AG (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972628-A1 | Indolizines and aza-analog derivatives thereof as CNS active compounds | SCHWARZ PHARMA AG (DE) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168125-A1 | INDOLIZINES AND AZA-ANALOG DERIVATIVES THEREOF AS CNS ACTIVE COMPOUNDS | INMT, AANAT, AZI2 | DRD3 230/4885DRD2 123/4885DRD4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.